| Dr Jason Farrell Skenazy, MD | |
|
935 Highland Blvd, Bozeman, MT 59715-6904 | |
| (406) 414-5300 | |
| Not Available |
| Full Name | Dr Jason Farrell Skenazy |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 14 Years |
| Location | 935 Highland Blvd, Bozeman, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134449267 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 41765 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bozeman Health Deaconess Hospital | Bozeman, MT | Hospital |
| Livingston Healthcare | Livingston, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bozeman Health Deaconess Hospital | 4688984164 | 233 |
News Archive
Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the "longevity" protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia.
Researchers at the University of British Columbia and Vancouver Coastal Health Research Institute have discovered that the genetic mechanism which destroys brain cells is responsible for early development of Alzheimer's Disease in people with Down Syndrome and for development of Alzheimer's Disease in general population - providing a potential new target for drugs that could forestall dementia in people with either condition.
Scientists at the University of Arizona Cancer Center and the Moffitt Cancer Center, led by Dr. Robert Gillies, have demonstrated that an advanced magnetic resonance imaging (MRI) method can non-invasively evaluate the cellular proliferation of tumor models of breast cancer.
Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.
› Verified 9 days ago
| Entity Name | Bozeman Health Deaconess Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619347390 PECOS PAC ID: 4688984164 Enrollment ID: O20151112002559 |
News Archive
Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the "longevity" protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia.
Researchers at the University of British Columbia and Vancouver Coastal Health Research Institute have discovered that the genetic mechanism which destroys brain cells is responsible for early development of Alzheimer's Disease in people with Down Syndrome and for development of Alzheimer's Disease in general population - providing a potential new target for drugs that could forestall dementia in people with either condition.
Scientists at the University of Arizona Cancer Center and the Moffitt Cancer Center, led by Dr. Robert Gillies, have demonstrated that an advanced magnetic resonance imaging (MRI) method can non-invasively evaluate the cellular proliferation of tumor models of breast cancer.
Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Farrell Skenazy, MD 935 Highland Blvd, Bozeman, MT 59715-6904 Ph: (406) 414-5300 | Dr Jason Farrell Skenazy, MD 935 Highland Blvd, Bozeman, MT 59715-6904 Ph: (406) 414-5300 |
News Archive
Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the "longevity" protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia.
Researchers at the University of British Columbia and Vancouver Coastal Health Research Institute have discovered that the genetic mechanism which destroys brain cells is responsible for early development of Alzheimer's Disease in people with Down Syndrome and for development of Alzheimer's Disease in general population - providing a potential new target for drugs that could forestall dementia in people with either condition.
Scientists at the University of Arizona Cancer Center and the Moffitt Cancer Center, led by Dr. Robert Gillies, have demonstrated that an advanced magnetic resonance imaging (MRI) method can non-invasively evaluate the cellular proliferation of tumor models of breast cancer.
Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.
› Verified 9 days ago
Dr. James Bruce Robertson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 711 W Main St, Bozeman, MT 59715 Phone: 406-551-2306 Fax: 855-544-7367 | |
Gregory Pritham, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 935 Highland Blvd Ste 2160, Bozeman, MT 59715 Phone: 406-414-5300 | |
John R Gannon, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 935 Highland Blvd Ste 2160, Bozeman, MT 59715 Phone: 406-414-5300 |